GlaxoSmithKline PLC said late Wednesday that the European Commission has given conditional marketing authorization to its anti-B-cell maturation antigen therapy belantamab mafodotin.
The British pharmaceuticals giant said belantamab mafodotin has been approved as a monotherapy for the treatment of multiple myeloma in adult patient, in whom the disease was unresponsive to previous treatment.
Earlier this month, the U.S. Food and Drug Administration approved the use of belantamab mafodotin as a monotherapy in the U.S. too.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.